# Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy

Source: https://onco.cc/trials/nct00129142/  
OnCo record `nct00129142` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Toremifene in Prostate cancer, run by GTx, completed.

## Summary

Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy is a phase 3 interventional study registered as NCT00129142 by GTx, with 1200 participants recorded, started 2003-10 and reaching its primary completion in 2007-11. Interventions recorded: Toremifene Citrate. Conditions recorded: Prostate Cancer, Osteoporosis, Fractures.

Linked to the drug Toremifene because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00129142
- Phase: 3
- Setting: A Randomized, Double Blind, Placebo Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy
- Sponsor: GTx
- Enrolled: 1200

## Sources

- ClinicalTrials.gov NCT00129142: https://clinicaltrials.gov/study/NCT00129142

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Toremifene](https://onco.cc/drugs/toremifene/)

---
JSON: https://onco.cc/api/v1/entities/nct00129142.json